Cargando…

PML is a ROS sensor activating p53 upon oxidative stress

Promyelocytic leukemia (PML) nuclear bodies (NBs) recruit partner proteins, including p53 and its regulators, thereby controlling their abundance or function. Investigating arsenic sensitivity of acute promyelocytic leukemia, we proposed that PML oxidation promotes NB biogenesis. However, physiologi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niwa-Kawakita, Michiko, Ferhi, Omar, Soilihi, Hassane, Le Bras, Morgane, Lallemand-Breitenbach, Valérie, de Thé, Hugues
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Rockefeller University Press 2017
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679165/ https://www.ncbi.nlm.nih.gov/pubmed/28931625 http://dx.doi.org/10.1084/jem.20160301

Ejemplares similares

Acute promyelocytic leukemia, arsenic, and PML bodies
por: de Thé, Hugues, et al.
Publicado: (2012)

Oxidative stress–induced assembly of PML nuclear bodies controls sumoylation of partner proteins
por: Sahin, Umut, et al.
Publicado: (2014)

Promyelocytic Leukemia Protein (PML) Controls Listeria monocytogenes Infection
por: Ribet, David, et al.
Publicado: (2017)

Exploration of nuclear body-enhanced sumoylation reveals that PML represses 2-cell features of embryonic stem cells
por: Tessier, Sarah, et al.
Publicado: (2022)

Author Correction: Exploration of nuclear body-enhanced sumoylation reveals that PML represses 2-cell features of embryonic stem cells
por: Tessier, Sarah, et al.
Publicado: (2023)

PML, SUMOylation, and Senescence
por: Ivanschitz, Lisa, et al.
Publicado: (2013)

JAK2(V617F) myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML
por: Dagher, Tracy, et al.
Publicado: (2020)

Role of Promyelocytic Leukemia (Pml) Sumolation in Nuclear Body Formation, 11s Proteasome Recruitment, and as(2)O(3)-Induced Pml or Pml/Retinoic Acid Receptor α Degradation
por: Lallemand-Breitenbach, Valérie, et al.
Publicado: (2001)

RING tetramerization is required for nuclear body biogenesis and PML sumoylation
por: Wang, Pengran, et al.
Publicado: (2018)

Publisher Correction: RING tetramerization is required for nuclear body biogenesis and PML sumoylation
por: Wang, Pengran, et al.
Publicado: (2018)

PML-Regulated Mitochondrial Metabolism Enhances Chemosensitivity in Human Ovarian Cancers
por: Gentric, Géraldine, et al.
Publicado: (2019)

In Vivo Activation of cAMP Signaling Induces Growth Arrest and Differentiation in Acute Promyelocytic Leukemia
por: Guillemin, Marie-Claude, et al.
Publicado: (2002)

Sumoylation in Physiology, Pathology and Therapy
por: Sahin, Umut, et al.
Publicado: (2022)

The DNA Binding Property of PML/RARA but Not the Integrity of PML Nuclear Bodies Is Indispensable for Leukemic Transformation
por: Liu, Xi, et al.
Publicado: (2014)

The PML hub: An emerging actor of leukemia therapies
por: Rérolle, Domitille, et al.
Publicado: (2023)

PML Degradation: Multiple Ways to Eliminate PML
por: Rabellino, Andrea, et al.
Publicado: (2013)

Regulating the p53 Tumor Suppressor Network at PML Biomolecular Condensates
por: Liebl, Magdalena C., et al.
Publicado: (2022)

Sirt3 is critical for p53-mediated ferroptosis upon ROS-induced stress
por: Jin, Ying, et al.
Publicado: (2020)

Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy
por: Wu, Hsin-Chieh, et al.
Publicado: (2021)

Regulation of NF-κB by PML and PML-RARα
por: Ahmed, Abrar, et al.
Publicado: (2017)

PML and PML-like exonucleases restrict retrotransposons in jawed vertebrates
por: Mathavarajah, Sabateeshan, et al.
Publicado: (2023)

Altered expression of the suppressors PML and p53 in glioblastoma cells with the antisense-EGF-receptor
por: Tian, X X, et al.
Publicado: (1999)

Gender, mutant p53 and PML: A growing “affaire” in tumor suppression and oncogenesis
por: Di Agostino, Silvia, et al.
Publicado: (2013)

Mad1 destabilizes p53 by preventing PML from sequestering MDM2
por: Wan, Jun, et al.
Publicado: (2019)

A Pin1/PML/P53 axis activated by retinoic acid in NPM-1c acute myeloid leukemia
por: Hleihel, Rita, et al.
Publicado: (2021)

PML goes to the centrosome
por: Wells, William A.
Publicado: (2005)

PML Bodies in Mitosis
por: Lång, Anna, et al.
Publicado: (2019)

Circadian behavior of mice deficient in PER1/PML or PER2/PML
por: Miki, Takao, et al.
Publicado: (2013)

BMK1 is involved in the regulation of p53 through disrupting the PML-MDM2 interaction
por: Yang, Q, et al.
Publicado: (2012)

ATM regulates cell fate choice upon p53 activation by modulating mitochondrial turnover and ROS levels
por: Sullivan, Kelly D, et al.
Publicado: (2014)

Expression and Function of PML-RARA in the Hematopoietic Progenitor Cells of Ctsg-PML-RARA Mice
por: Wartman, Lukas D., et al.
Publicado: (2012)

PML isoforms in response to arsenic: high-resolution analysis of PML body structure and degradation
por: Hands, Katherine J., et al.
Publicado: (2014)

Severe early natalizumab-associated PML in MS: Effective control of PML-IRIS with maraviroc
por: Bsteh, Gabriel, et al.
Publicado: (2017)

The p97/VCP segregase is essential for arsenic-induced degradation of PML and PML-RARA
por: Jaffray, Ellis G., et al.
Publicado: (2023)

Puromycin-based vectors promote a ROS-dependent recruitment of PML to nuclear inclusions enriched with HSP70 and Proteasomes
por: Moran, Diarmuid M, et al.
Publicado: (2009)

Immunosuppressive therapy in dermatology and PML
por: Sterry, Wolfram, et al.
Publicado: (2009)

Differential Roles of PML Isoforms
por: Nisole, Sébastien, et al.
Publicado: (2013)

Is PML a Tumor Suppressor?
por: Mazza, Massimiliano, et al.
Publicado: (2013)

Tax as a therapeutic target in ATL
por: Dassouki, Zeina, et al.
Publicado: (2015)

Tax as a therapeutic target in ATL
por: Dassouki, Zeina, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_t01lvmc6qpgv1biodm77s14j20